|
Mechanism50S subunit inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date01 Nov 1991 |
|
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
ZHCX002序贯给药在成人社区获得性肺炎患者中的药代动力学、安全性和疗效探索的I期临床研究
[Translation] A phase I clinical study to explore the pharmacokinetics, safety and efficacy of sequential administration of ZHCX002 in adult patients with community-acquired pneumonia
主要目的:考察注射用阿奇霉素和阿奇霉素干混悬剂序贯给药在成人社区获得性肺炎患者体内的药代动力学特征。
次要目的:
1.评价注射用阿奇霉素治疗成人社区获得性肺炎患者的安全性。
2. 评价注射用阿奇霉素治疗成人社区获得性肺炎患者的有效性。
3. 探索成人社区获得性肺炎患者PK/PD和PK/安全性的关系。
[Translation] Primary objective: To investigate the pharmacokinetic characteristics of azithromycin for injection and azithromycin dry suspension in adults with community-acquired pneumonia after sequential administration.
Secondary objectives:
1. To evaluate the safety of azithromycin for injection in the treatment of adult patients with community-acquired pneumonia.
2. To evaluate the effectiveness of azithromycin for injection in the treatment of adult patients with community-acquired pneumonia.
3. To explore the relationship between PK/PD and PK/safety in adult patients with community-acquired pneumonia.
100 Clinical Results associated with Zhihe (Shandong) Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Zhihe (Shandong) Pharmaceutical Co., Ltd.
100 Deals associated with Zhihe (Shandong) Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Zhihe (Shandong) Pharmaceutical Co., Ltd.